Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A BREAKTHROUGH TECHNOLOGY DESIGNED TO PRESERVE SIGHT AND HALTING VISION LOSS ASSOCIATED WITH A RANGE OF RETINAL DISEASE BY PREVENTING THE DEATH OF KEY RETINAL CELLS .

Project description

The future looks brighter for organ disease treatment

Millions worldwide suffer from severe organ pathologies such as acute liver failure and retinal diseases, with limited effective treatments available. These conditions often cause irreversible damage and can be life-threatening. Despite medical advancements, preventing cell death and preserving organ function remain significant challenges in treatment. With this in mind, the EU-funded SeaBeEYE project aims to develop innovative drugs designed to halt cell death pathways and preserve vision loss in patients suffering from degenerative retinal disorders. This initiative targets retinal diseases with groundbreaking drugs. Following promising in vivo results the drugs are poised for clinical trials. This represents a significant step in pre-clinical development for eye diseases.

Objective

I am the CEO and Cofounder of SeaBeLife, a French biotechnology company developing First-In-Class drugs to treat severe pathologies affecting our vital organs for which there are no effective treatments. We develop an innovative therapeutic approach protected by 4 patents and with a lead program to treat Acute Liver Failure and a second program to preserve sight and halting vision loss associated with a range of retinal disease by preventing the death of key retinal cells. We are developing a first-in-class drug based on a dual-targeted approach, capable of stopping directly and simultaneously two forms of regulated cell death pathways known to be involved in triggering of numerous acute and chronic pathologies and contributing to organ damage. Our molecule protects the cells, prevents tissue damage, and finally preserves and restores organ function. SeaBeLife is the only company worldwide developing such a therapeutic approach. Our molecule has a direct protective effect on cells and has the potential to prevent evolution to severe life-threatening form. We have already obtained very convincing in vivo results in several highly predictive models. Our molecules were tested on pharmacologically relevant murine models and have shown no toxicity and strong efficacy. SeaBeLife is composed of an experienced and complementary operational team managing by two women and supported by a scientific and strategic advisory board with scientific and medical experts of extensive expertise in drug development. We have already raised 4.3M€ to develop our technology and we are ready to bring our molecules to the clinic and validate its safety and efficacy. The main milestones over the next 2 years will be the production of compliant clinical batches and the realization of phase 1 and phase 2a clinical trials. The WomenTechEU award and funding will allow us to gain visibility as women entrepreneurs and also to take an important step in our pre-clinical development for eye diseases.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-CSA - HORIZON Coordination and Support Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIE-2022-SCALEUP-02

See all projects funded under this call

Coordinator

SEABELIFE SAS
Net EU contribution
€ 75 000,00
Address
PLACE GEORGES TEISSIER, STATION BIOLOGIQUE DE ROSCOFF
29680 Roscoff
France
Region
Bretagne Bretagne Finistère
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data